npg

Hypertensive diseases in pregnancy and breast cancer risk

S Opdahl[*,1], PR Romundstad[1], MDK Alsaker[1,2] and LJ Vatten[1]

[1]Department of Public Health and Community Medicine, Faculty of Medicine, Norwegian University of Science and Technology, NTNU, Postbox 8905, MTFS, Trondheim N-7491, Norway; [2]Department of Oncology, St Olavs Hospital, Trondheim N-7006, Norway

BACKGROUND: Hypertensive diseases in pregnancy may be associated with a reduced risk of breast cancer. Most previous studies are small and have shown conflicting results.

METHODS: In a cohort of 919 712 women who gave their first birth between 1967 and 2008, with linkage of information from two national registries, we assessed whether women with pregnancy hypertensive diseases are at reduced breast cancer risk. We used Cox regression to estimate hazard ratios (HRs) with 95% confidence intervals (CI).

RESULTS: Compared with women with a normotensive first pregnancy, women with hypertension or preeclampsia in their first pregnancy had a reduced breast cancer risk (HR 0.83, 95% CI 0.77, 0.90). A reduced risk was consistently observed for hypertensive disease in any pregnancy, for recurrent hypertensive disease in pregnancy, and before and after 50 years of age at breast cancer diagnosis. The association was strongest for women with hypertension in pregnancy, who delivered at term/post-term (HR 0.81, 95% CI 0.75, 0.88) or had a child of average birth weight (HR 0.77, 95% CI 0.69, 0.85).

CONCLUSION: Women with pregnancy hypertensive diseases are at reduced breast cancer risk. Whether this association can be attributed to pregnancy-specific events or to underlying biological traits remains unclear.

British Journal of Cancer (2012) **107,** 176–182. doi:10.1038/bjc.2012.195   www.bjcancer.com
Published online 10 May 2012
© 2012 Cancer Research UK

Pregnancy is associated with a long-term reduction in breast cancer risk (Kelsey *et al*, 1993). The underlying mechanisms are not fully understood, but the reduced risk has been attributed to the differentiation of breast tissue cells induced by pregnancy hormones (Britt *et al*, 2007). To improve our understanding of the role of pregnancy in breast cancer development, some investigators have studied long-term effects of certain pregnancy characteristics or complications (Nechuta *et al*, 2010), including hypertensive disorders in pregnancy such as preeclampsia and gestational hypertension.

Preeclampsia is clinically characterised by hypertension and proteinuria in the second half of pregnancy, and occurs in about 5% of primiparous women (Trogstad *et al*, 2011). Gestational hypertension and preeclampsia appear to be closely related conditions that may originate from the same underlying disorder (Villar *et al*, 2006). Studies that have examined the association of preeclampsia and/or hypertension in pregnancy with later breast cancer risk have shown conflicting results and variously reported reduced risk (Polednak and Janerich, 1983; Thompson *et al*, 1989; Troisi *et al*, 1998; Cohn *et al*, 2001; Vatten *et al*, 2002a, 2007; Innes and Byers, 2004; Terry *et al*, 2007), no association (Mogren *et al*, 2001; Cnattingius *et al*, 2005; Ma *et al*, 2010), or an increased risk (Talamini *et al*, 1997; Calderon-Margalit *et al*, 2009). Limitations of most previous studies include a relatively young age of the participants and a small number of exposed women who have later developed breast cancer.

It is not known whether an association of hypertensive diseases in pregnancy with later breast cancer risk may be attributed to events during that particular pregnancy, or to underlying traits that are both associated with susceptibility to pregnancy hypertension and with breast cancer risk (Innes and Byers, 1999; Nechuta *et al*, 2010). If the association of pregnancy hypertensive diseases with breast cancer risk differs depending on offspring sex (Terry *et al*, 2007; Troisi *et al*, 2007; Vatten *et al*, 2007), on the number of hypertensive pregnancies (Terry *et al*, 2007), or on the severity of the hypertensive condition (Vatten *et al*, 2002a; Terry *et al*, 2007), this may support a pregnancy-specific effect.

We have updated and extended the Norwegian data (Vatten *et al*, 2002a; Vatten *et al*, 2007) with an addition of 218 706 participants and 6696 breast cancer cases, based on a linkage between the Medical Birth Registry of Norway and the Cancer Registry of Norway, and investigated the association of hypertensive diseases in pregnancy with later breast cancer risk. The increased statistical power enabled us to obtain more precise estimates for the previously reported associations. In addition, we have investigated whether the association is similar for hypertensive diseases in the first and in any pregnancy, whether the association could be modified by subgroup or severity of hypertensive disease, and whether a dose-risk association could be present, as indicated by the recurrence of hypertensive disease in pregnancy.

METHODS

Study population

Data were obtained from the Medical Birth Registry of Norway and the Cancer Registry of Norway. In the Medical Birth Registry, information on all births has been collected since 1967, and recorded in a standardised notification form completed by midwives and doctors. A total of 972 331 women who gave their first birth between 1 January 1967 and 31 December 2008, and had

Epidemiology

singleton births only, were eligible for follow-up. We excluded 96 women who were diagnosed with breast cancer before their first birth and 2481 women who had a period of emigration before their first birth, and thus could not be followed for breast cancer occurrence before their first birth. We also excluded 50 042 women (5%) with missing information on the following factors related to their first pregnancy: duration of pregnancy, offspring sex, and offspring birth weight. The remaining 919 712 women were followed for breast cancer occurrence.

Study factors

During the study period (1967–2008), nearly 100% of pregnant women in Norway have attended the publicly financed routine antenatal care (Backe, 1992). At each visit, blood pressure is measured and urine is examined for protein. Information from these visits and from medical examinations at the delivery unit is included in the notification form that is sent to the Medical Birth Registry. Hypertensive diseases in pregnancy are classified according to the International Classification of Diseases (ICD): ICD-8 was used throughout 1998, and ICD-10 from 1999. Hypertensive diseases in pregnancy were defined as hypertension in pregnancy (ICD-8: 637.0 and 637.2, ICD-10: O16) and as preeclampsia/eclampsia (ICD-8: 637.4–9, ICD-10: O13, O14 and O15; NIPH, 2009).

From the Medical Birth Registry, we also obtained information on the following factors: date of delivery, age at first birth, total number of pregnancies, offspring's birth weight in grams, offspring sex, and duration of pregnancy in completed weeks (based on ultrasound examination in 24% of the pregnancies and on the first day of the last menstrual period in 76%).

Follow-up

The unique identification number of Norwegian citizens was used to link information from the Medical Birth Registry to information on cancer occurrence from the Cancer Registry of Norway, which also includes information on vital status and emigration, as recorded by the Population Registry at Statistics Norway. Invasive breast cancer was registered according to the ICD, 7th edition (ICD-7, code 170). Breast cancer diagnoses were based on histological (99.4%), cytological (0.5%), or clinical (0.1%) examination. Reporting of new diagnoses of cancer to the Cancer Registry is mandatory by law, and follow-up for breast cancer is considered practically complete (Larsen et al, 2007). Women were followed from their first birth until the date of breast cancer diagnosis, death, emigration, or until 31 December 2008, whichever came first.

The study was approved by the regional committee for medical research ethics.

Statistical analyses

The association of hypertensive diseases in pregnancy with breast cancer incidence was assessed using the Cox proportional hazards models to estimate hazard ratios (HRs) with 95% confidence intervals (CI). We studied the association of preeclampsia/eclampsia (PE) and hypertension (HIP) in a woman's first pregnancy with breast cancer risk, both using PE and HIP combined, and as separate entities. We also investigated whether PE/HIP in any pregnancy was associated with the risk of breast cancer, where women contributed person-time to the exposed category from their first registered PE/HIP pregnancy. Among women with two or more births, we also investigated the association of PE/HIP in the first or second pregnancy, and in both pregnancies.

To investigate whether the association could vary by menopausal status at diagnosis, we conducted separate analyses with follow-up until 50 years of age (<50 years) and beyond 50 years ($\geqslant 50$ years), using 50 years as a crude indicator for menopausal

status. We also conducted a sensitivity analysis for women followed from 60 years of age. Also, we studied whether the association of PE/HIP in the first pregnancy could be modified by duration of pregnancy (<37 or $\geqslant 37$ weeks), offspring birth weight (<3000, 3000–3999 or $\geqslant 4000$ g), and by offspring sex.

In a separate analysis, we studied whether the duration of a woman's first pregnancy was associated with breast cancer risk, stratified by whether PE/HIP occurred or not in the first pregnancy. The aim of this analysis was to clarify the role of preterm birth for the association of PE/HIP with breast cancer risk. Analyses of trend were performed by scoring each category of duration of pregnancy with the median value within that category. In the analysis, the categories were treated as a continuous variable, and we estimated HRs with 95% CI per week of longer duration of pregnancy.

For all analyses, attained age was used as the time scale. We adjusted for maternal birth year (in 5-year categories), age at first birth (<20, 20–24, 25–29, 30–34, or $\geqslant 35$ years), parity (1, 2, 3, 4, or $\geqslant 5$), and marital status at first birth (married/cohabiting or single). Parity was treated as a time-dependent variable; thus, a woman entered a category of higher parity whenever a new birth occurred. We assessed heterogeneity of the HRs across strata of the different pregnancy characteristics by likelihood ratio tests, and compared models with and without product terms.

Proportionality between hazards was checked by comparing log minus log plots of survival and by performing tests based on Schoenfeld residuals. Assumptions were met for all the previously described models. In a sensitivity analysis, we investigated whether inclusion of women with missing information on offspring birth weight and sex, and duration of pregnancy, could alter the main results.

All analyses were conducted using Stata version 11.1 MP for Windows (Stata Corp., College Station, TX, USA).

RESULTS

A total of 919 712 women without breast cancer at baseline were followed for approximately 19 million person years. Median time of follow-up was 20.4 years (interquartile range (IQR) 10.0–31.8 years) for women with a normotensive first pregnancy, and 17.8 (IQR 7.7–28.7 years) for women with PE/HIP in the first pregnancy. The difference in follow-up time was largely explained by an increase in the frequency of PE/HIP during the observation period. During follow-up, 15 856 women were diagnosed with invasive breast cancer. Mean age at diagnosis was similar in the two groups (49.0 years, s.d. 8.4 years). Women with PE/HIP in their first pregnancy were older at first birth, had pregnancies of shorter duration, their children were smaller, and there was a higher proportion of male offspring after PE/HIP compared with normotensive first pregnancies. Characteristics of the study participants are shown in Table 1.

Women who had a hypertensive disease in their first pregnancy were at 17% lower risk of breast cancer than women with a normotensive first pregnancy (HR 0.83, 95% CI 0.77, 0.90; Table 2). The lower risk was present both for isolated hypertension (HR 0.78, 95% CI 0.68, 0.89) and for PE (HR 0.86, 95% CI 0.79, 0.94). Estimates were similar for women who had PE/HIP in the first and second pregnancy (HR 0.84, 95% CI 0.70, 1.01) and for women with PE/HIP in any pregnancy (HR 0.84, 95% CI 0.79, 0.89). The associations were similar for breast cancer diagnosed before and after 50 years of age (Table 3), and for women 60 years and older (results not shown).

Tables 4 and 5 show associations of PE/HIP in first pregnancy according to pregnancy characteristics and offspring sex. There was no evidence for a stronger association related to the severity of hypertension, as indicated by preterm birth or low offspring birth weight. In fact, the association was more pronounced among women with average offspring birth weight (HR 0.77, 95% CI 0.69, 0.85), and the negative association was restricted to women who

Epidemiology

gave birth after 37 completed weeks of pregnancy (HR 0.81, 95% CI 0.75, 0.88). Overall, women with PE/HIP in their first pregnancy were at reduced risk of breast cancer, regardless of whether their

Table I Characteristics of the study participants, according to presence or absence of hypertensive disease in first pregnancy

	Normotensive	PE/HIP
Median time in study (IQR)	20.4 (10.0–31.8)	17.8 (7.7–28.7)
Mean age at breast cancer diagnosis (s.d.)	49.0 (8.4)	48.9 (8.8)
Median birth year (IQR)	1962 (1953–1971)	1964 (1955–1973)
Age at first birth, years		
<20	107 734 (12.5)	5595 (9.9)
20–24	341 394 (39.5)	20 329 (36.0)
25–29	274 815 (31.8)	18 853 (33.4)
30–34	107 038 (12.4)	8352 (14.8)
≥35	32 341 (3.7)	3277 (5.8)
Parity		
1	202 401 (23.4)	15 890 (28.2)
2	401 324 (46.5)	25 673 (45.5)
3	200 802 (23.3)	11 612 (20.6)
4	46 271 (5.4)	2576 (4.6)
≥5	12 509 (1.4)	654 (1.2)
Offspring sex in first pregnancy		
Male	443 529 (51.4)	29 901 (53.0)
Female	419 778 (48.6)	26 504 (47.0)
Birth weight in first pregnancy (g)		
<3000	143 408 (16.6)	18 417 (32.7)
3000–4000	597 668 (69.2)	30 399 (53.9)
≥4000	122 246 (14.2)	7590 (13.5)
Duration of first pregnancy[a] (weeks)		
<37	50 005 (5.8)	8704 (15.4)
≥37	813 17 (94.2)	47 702 (84.6)
Marital status at first birth		
Married/cohabiting	719 525 (83.3)	48 266 (85.6)
Single	143 782 (16.7)	8139 (14.4)

Abbreviations: HIP = hypertension in pregnancy; IQR = interquartile range; PE = preeclampsia/eclampsia. Number of women (%). [a]Based on ultrasound examination in 24% of the pregnancies and on the first day of the last menstrual period in 76%.

offspring was a male (HR 0.80, 95% CI 0.72, 0.88) or a female (HR 0.88, 95% CI 0.79, 0.97), and there was no clear risk difference by offspring sex among women who gave birth after 37 weeks. However, among women with a preterm first birth, the reduced breast cancer risk associated with PE/HIP was restricted to women with a male offspring.

Table 6 shows duration of first pregnancy in relation to breast cancer risk, stratified by PE/HIP status. There was a reduction in risk with increasing duration of first pregnancy, and the inverse association was more pronounced among women with PE/HIP than among normotensive women (HR per week longer duration 0.95, 95% CI 0.93, 0.98 and 0.99, and 95% CI 0.98, 1.00, respectively). Crude absolute incidence rates among women whose first pregnancy was shorter than 32 weeks were similar, regardless of the PE/HIP status.

In all analyses, adjustment for potentially confounding factors marginally strengthened the associations, compared with models with adjustment for age alone. There was no change in the main results when women with missing information on offspring birth weight and sex, and duration of pregnancy were included in the analyses.

DISCUSSION

In this prospective study of 919 712 women, hypertensive diseases in pregnancy was associated with a reduced risk of breast cancer, of a similar magnitude as previously reported (Vatten *et al*, 2002a, 2007). The reduced risk was similar for PE/HIP in the first pregnancy, in any pregnancy, and for recurrent PE/HIP, and for breast cancer diagnosed both before and after 50 years of age. The lowest risk was observed for women who developed PE/HIP and had a term or post-term birth, or a child of average birth weight.

Our results correspond to those of most previous studies in reporting a moderately reduced risk (Polednak and Janerich, 1983; Thompson *et al*, 1989; Troisi *et al*, 1998; Cohn *et al*, 2001; Innes and Byers, 2004; Terry *et al*, 2007), regardless of whether preeclampsia (Polednak and Janerich, 1983; Troisi *et al*, 1998; Cohn *et al*, 2001; Innes and Byers, 2004; Terry *et al*, 2007) or hypertension in pregnancy (Thompson *et al*, 1989; Troisi *et al*, 1998; Cohn *et al*, 2001; Terry *et al*, 2007) was studied. All but one (Cohn *et al*, 2001) of those studies had a retrospective design, and the assessment of hypertensive disease in pregnancy was based on patients' recall in some studies (Thompson *et al*, 1989; Troisi *et al*, 1998; Terry *et al*, 2007) and on hospital records in others (Polednak and Janerich, 1983; Cohn *et al*, 2001; Innes and Byers, 2004). However, in a Swedish registry-based study using prospective data, the investigators found no association for hypertensive

Table 2 Hypertensive diseases in pregnancy (PE/HIP) and breast cancer risk in 919 712 Norwegian women

	Person-years	Cases	Rate[a]	HR[b] (95% CI)	HR[c] (95% CI)
PE/HIP in first pregnancy					
No	17 919 955	15 113	84	1 (ref)	1 (ref)
Yes	1 047 052	743	71	0.86 (0.80, 0.92)	0.83 (0.77, 0.90)
HIP	331 494	237	71	0.81 (0.71, 0.92)	0.78 (0.68, 0.89)
PE	715 559	506	71	0.88 (0.81, 0.97)	0.86 (0.79, 0.94)
PE/HIP in first and/or second pregnancy[d]					
No	12 458 204	11 758	94	1 (ref)	1 (ref)
PE/HIP in first, but not second pregnancy	558 440	435	78	0.86 (0.78, 0.95)	0.85 (0.77, 0.93)
PE/HIP in second, but not first pregnancy	259 294	241	93	0.93 (0.82, 1.06)	0.91 (0.80, 1.03)
PE/HIP in first and second pregnancy	140 131	117	83	0.89 (0.74, 1.07)	0.84 (0.70, 1.01)
PE/hypertension in any pregnancy					
Never	17 533 025	14 773	84	1 (ref)	1 (ref)
Ever	1 433 982	1083	76	0.84 (0.79, 0.89)	0.84 (0.79, 0.89)

Abbreviations: CI = confidence intervals; HIP = hypertension in pregnancy; HR = hazard ratio; PE = preeclampsia/eclampsia. [a]Cases/100 000 person-years, unadjusted. [b]Adjusted for age. [c]Adjusted for age, birth cohort, parity, age at first birth, and marital status at first birth. [d]Women with two or more pregnancies, followed from the date of their second birth.

Table 3 Hypertensive diseases in pregnancy (PE/HIP) and breast cancer risk in 919 712 Norwegian women, stratified by age

	Premenopausal (<50 years)			Postmenopausal (⩾50 years)		
	Cases	Rate[a]	HR[b] (95% CI)	Cases	Rate[a]	HR[b] (95% CI)
PE/HIP in first pregnancy						
No	8013	53	1 (ref)	7038	264	1 (ref)
Yes	405	45	0.84 (0.76, 0.93)	337	228	0.83 (0.75, 0.93)
HIP	130	46	0.81 (0.68, 0.96)	106	206	0.75 (0.62, 0.91)
PE	275	44	0.86 (0.76, 0.97)	231	240	0.88 (0.77, 1.00)
PE/hypertension in first and/or second pregnancy[c]						
No	6281	61	1 (ref)	5427	255	1 (ref)
PE/HIP in first, but not second pregnancy	237	50	0.83 (0.73, 0.94)	197	227	0.88 (0.76, 1.01)
PE/HIP in second, but not first pregnancy	126	60	0.91 (0.76, 1.08)	114	239	0.91 (0.75, 1.07)
PE/HIP in first and second pregnancy	69	59	0.89 (0.70, 1.13)	48	213	0.79 (0.59, 1.08)
PE/HIP in any pregnancy						
Never	7841	52	1 (ref)	6871	266	1 (ref)
Ever	577	48	0.84 (0.77, 0.91)	504	224	0.85 (0.77, 0.93)

Abbreviations: CI = confidence intervals; HIP = hypertension in pregnancy; HR = hazard ratio; PE = preeclampsia/eclampsia. [a]Cases/100 000 person-years, unadjusted. [b]Adjusted for age, birth cohort, parity, age at first birth, and marital status at first birth. [c]Women with two or more pregnancies, followed from the date of their second birth in analyses of women <50 years, and from age 50 years in analyses of women ⩾50 years.

Table 4 PE/HIP in first pregnancy and breast cancer risk in 919 712 Norwegian women, stratified by offspring birth weight and duration of pregnancy

Pregnancy characteristic	PE/HIP in first pregnancy	Cases	Rate[a]	HR[b] (95% CI)
Offspring birth weight[c] *(in g)*				
<3000	Normotensive	2695	88	1 (ref)
	PE/HIP	273	82	0.92 (0.81, 1.05)
3000–3999	Normotensive	10 405	84	1 (ref)
	PE/HIP	369	64	0.77 (0.69, 0.85)
⩾4000	Normotensive	2013	84	1 (ref)
	PE/HIP	101	73	0.86 (0.71, 1.05)
Duration of pregnancy[d] *(in weeks)*				
⩾37	Normotensive	14 189	84	1 (ref)
	PE/HIP	629	69	0.81 (0.75, 0.88)
<37	Normotensive	924	89	1 (ref)
	PE/HIP	114	85	0.96 (0.79, 1.17)

Abbreviations: CI = confidence intervals; HIP = hypertension in pregnancy; HR = hazard ratio; PE = preeclampsia/eclampsia. [a]Cases/100 000 person-years, unadjusted. [b]Adjusted for age, birth cohort, parity, age at first birth and marital status at first birth. [c]P-value from LR-test of interaction term 0.16. [d]P-value from LR-test of interaction term 0.09.

Table 5 PE/HIP in first pregnancy and breast cancer risk in 919 712 Norwegian women, stratified by offspring sex

	Male offspring			Female offspring		
	Cases	Rate[a]	HR[b] (95% CI)	Cases	Rate[a]	HR[b] (95% CI)
PE/HIP in first pregnancy[c]						
No	7794	85	1 (ref)	7319	84	1 (ref)
Yes	379	68	0.80 (0.72, 0.88)	364	74	0.88 (0.79, 0.97)
PE/HIP in first pregnancy						
⩾37 weeks and normotensive[d]	7283	84	1 (ref)	6906	84	1 (ref)
⩾37 weeks and PE/HIP	326	67	0.79 (0.70, 0.88)	303	71	0.83 (0.74, 0.94)
<37 weeks and normotensive[e]	511	87	1 (ref)	416	91	1 (ref)
<37 weeks and PE/HIP	53	73	0.82 (0.62, 1.09)	61	98	1.14 (0.86, 1.49)

Abbreviations: CI = confidence intervals; HIP = hypertension in pregnancy; HR = hazard ratio; PE = preeclampsia/eclampsia. [a]Cases/100 000 person-years, unadjusted. [b]Adjusted for age, birth cohort, parity, age at first birth and marital status at first birth. [c]P-value from LR-test of interaction term 0.23. [d]P-value from LR-test of interaction term 0.51. [e]P-value from LR-test of interaction term 0.18.

Epidemiology

180

Table 6 Duration of first pregnancy and breast cancer risk in 919 712 Norwegian women, stratified by PE/HIP status

	Normotensive			PE/HIP		
	Cases	Rate[a]	HR[b] (95% CI)	Cases	Rate[a]	HR[b] (95% CI)
Duration of first pregnancy (weeks)						
<32	200	87	1 (ref)	21	88	1 (ref)
32–36	724	89	1.01 (0.86, 1.18)	93	84	0.83 (0.51, 1.33)
37	565	88	0.99 (0.84, 1.17)	52	76	0.74 (0.45, 1.23)
38	1211	85	0.96 (0.82, 1.11)	80	69	0.68 (0.42, 1.11)
39	2660	85	0.94 (0.82, 1.09)	163	85	0.81 (0.51, 1.27)
40	4036	86	0.95 (0.82, 1.09)	162	68	0.64 (0.40, 1.01)
41	3326	83	0.92 (0.80, 1.06)	100	58	0.55 (0.34, 0.88)
⩾42	2391	81	0.90 (0.78, 1.04)	72	58	0.56 (0.34, 0.91)
Per week[c]	15 113	84	0.99 (0.98, 1.00)	743	71	0.95 (0.93, 0.98)

Abbreviations: CI = confidence intervals; HIP = hypertension in pregnancy; HR = hazard ratio; PE = preeclampsia/eclampsia. [a]Cases/100 000 person-years, unadjusted. [b]Adjusted for age, birth cohort and parity, age at first birth and marital status at first birth. [c]P-value from LR-test of interaction term 0.22.

diseases combined, but estimates were not adjusted for other potentially confounding factors (Cnattingius *et al*, 2005). In two other prospective studies, there was no association of self-reported (Ma *et al*, 2010) or registry-based (Mogren *et al*, 2001) preeclampsia with breast cancer risk. In a hospital-based prospective study from Israel (Calderon-Margalit *et al*, 2009) and in a retrospective study from Italy, based on self-reported data (Talamini *et al*, 1997), the researchers reported an increased risk of breast cancer associated with preeclampsia and hypertensive disease in pregnancy, respectively. The reasons for the divergence in results between studies are unclear, but may be related to study size, exposure definition, lack of adjustment for potential confounding, genetic factors, or to modification by unmeasured or unknown factors. For simplicity, characteristics and main results of the referred previous studies are summarised in Table 7.

Our study encompassed all women who gave their first birth in Norway during the study period, and information on incident breast cancer was collected prospectively. Therefore, bias in selection or information recall is unlikely. Misclassification of breast cancer diagnoses is most likely negligible, as reporting of cancer to the Cancer Registry of Norway is mandatory by law, and the breast cancer diagnoses were based on pathology reports for 99.9% of the women for whom a breast cancer diagnosis was reported.

We did not have information on body mass index, which could have confounded the association of hypertensive conditions in pregnancy with breast cancer risk (Nechuta *et al*, 2010). Overweight and obesity are associated with an increased risk of developing hypertensive diseases during pregnancy (Villar *et al*, 2006), and a high body mass index during the reproductive years is associated with reduced risk of premenopausal breast cancer (Friedenreich, 2001). For postmenopausal women, overweight is generally associated with an increased risk (Friedenreich, 2001), although there are indications that overweight at a young age may be associated with a modestly reduced risk, of postmenopausal breast cancer (Baer *et al*, 2010). We found a similar reduction in risk both before and after 50 years of age, which may suggest that the association cannot be fully attributed to confounding by overweight. The results of one study indicated that adjustment for body mass index may attenuate the association of hypertensive diseases in pregnancy with breast cancer risk among premenopausal, but not in postmenopausal women (Terry *et al*, 2007). However, in most studies that have been able to evaluate the possible confounding by body mass index, estimates have remained unchanged after adjustment (Thompson *et al*, 1989; Talamini *et al*, 1997; Troisi *et al*, 1998; Ma *et al*, 2010). Other potentially confounding factors include insulin resistance and diabetes mellitus, which are strongly related to the risk of preeclampsia (Sohlberg *et al*, 2012) and may also be related to breast cancer risk (Bjorge *et al*, 2010).

The accuracy of the exposure in our study has not been validated. The diagnostic criteria for preeclampsia have changed over time and are still debated (Trogstad *et al*, 2011). Although some misclassification may have occurred, it is likely to be non-differential with respect to future breast cancer diagnosis, and its effect would lead to conservative estimates. We had no direct information on menopausal status, but used 50 years of age as a crude indicator. In addition, the cohort is still relatively young. This could have obscured potential differences in association by menopausal status, but the similarly reduced risks for women 60 years or older suggest that the association was not likely to be modified by menopausal status. We used duration of pregnancy as an indicator for the severity of hypertensive disease in pregnancy. Because of the induction of labour in women with a severe hypertensive disease, duration of pregnancy may be regarded as an intermediate variable, and we cannot exclude the possibility that this may introduce a bias (Cole and Hernan, 2002). However, duration of pregnancy is not strongly related to breast cancer risk, and therefore, the potential bias would be negligible. Finally, our results should be interpreted considering that multiple tests were carried out, and although these were related, chance findings cannot be ruled out.

There is an inverse association of parity with breast cancer risk, where each additional pregnancy confers additional protection. This effect has been attributed to the repeated exposure to pregnancy hormones (Kelsey *et al*, 1993). If pregnancy hypertensive diseases influence breast cancer risk through pregnancy-specific events, such as altering the hormonal milieu compared with that of normotensive pregnancies (Innes and Byers, 1999; Tamimi *et al*, 2003), one might expect that women who experience more than one hypertensive pregnancy would be at particularly low risk. However, the risk reduction among women with recurrent hypertensive disease in pregnancy was not particularly strong, in contrast to reports by others (Terry *et al*, 2007).

Possible differences in the association by offspring sex were weaker in this analysis than previously reported (Vatten *et al*, 2007). In preeclampsia, the duration of pregnancy tends to be longer if the fetus is a male (Vatten and Skjaerven, 2004), but it is unclear whether this puzzling phenomenon could disturb the sex-specific analyses of hypertensive diseases and breast cancer risk.

The inverse association of duration of first pregnancy with breast cancer risk was slightly attenuated compared with what has previously been reported (Vatten *et al*, 2002b). A possible impact of duration of pregnancy on breast cancer risk has been attributed to increased differentiation of breast tissue in women with longer exposure to pregnancy hormones (Nechuta *et al*, 2010). In our study, the association was particularly strong among women who had a hypertensive disease in their first pregnancy. Preeclampsia is thought to originate from an abnormal placentation and/or an abnormal maternal response to the pregnancy (Trogstad *et al*, 2011). There are indications that early preeclampsia may be more

Table 7 Selected characteristics and main results of previous studies of hypertensive diseases in pregnancy and breast cancer risk[a]

Study and location	Cases/controls	Age at diagnosis (years)	Exposure assessment	Exposure (prevalence[b], %)	HR/RR/OR (95% CI)	Covariates
Cohort studies						
Cohn et al, 2001, United States	146/3658	Mean 54.2	Birth records	P in any pregnancy (NR)	0.60[c]	Age
				Blood pressure increase Q1 vs Q4 (NR)	0.50 (0.31, 0.82)	Age, birth year, parity, age at first birth, maternal weight gain
Mogren et al, 2001, Sweden	870/40 081	Range 25–71 Median 48	Swedish Birth Register (ICD-8, ICD-9)	P/HIP in any pregnancy (8.3)	No association (estimate NR)	NR
Cnattingius et al, 2005, Sweden	2216/311 803	95% of cases <50	Swedish Birth Register (ICD-8, ICD-9)	PE/HIP in first pregnancy (6.8)	1.05[c]	—
Vatten et al, 2002a, Norway	5474/689 183	Range <30–80	Medical Birth Registry of Norway (ICD-8)	PE/HIP in first pregnancy (6.2)	0.81 (0.71, 0.91)	Age, year of diagnosis, age at first birth, and parity
Vatten et al, 2007, Norway	9160/691 846	Range <30–84	Medical Birth Registry of Norway (ICD-8)	PE/HIP in first pregnancy (6.2)	0.86 (0.78, 0.94)	Age, age at first birth, duration of pregnancy, parity, marital status, and offspring sex
Calderon-Margalit et al, 2009, Israel	2024/35 903	NR	Birth records	P in any pregnancy (2.9)	1.37 (1.06, 1.78)	Age at first birth and parity
Ma et al, 2010, United States	1768/29 691	Postmenopausal <80	Self-reported	P in last pregnancy (NR)	0.98 (0.73, 1.33)	Age, race, family history of breast cancer, age at menarche, hormone therapy use, body mass index, and parity
				P in other pregnancy (NR)	0.77 (0.58, 1.02)	
Case–control studies						
Polednak and Janerich, 1983, United States	314/628	All cases <45	Birth records	PE in first pregnancy (2.4)	0.28 (0.08, 1.00)	Location and time of birth (matched), age at first birth
Thompson et al, 1989, United States	4668/4635	Range 20–54	Self-reported	HT before or during last pregnancy (4.9)	0.73 (0.59, 0.92)	Age and geographic region (matched), parity, age at first term pregnancy, and total duration of breast feeding. Body mass (not included in final model)
Talamini et al, 1997, Italy	2569/2588	Range 23–74 Median 55	Self-reported	HIP in any pregnancy (0.5)	1.8 (1.0, 3.4)	Study area, age, education, parity, body mass index, and menopausal status
Troisi et al, 1998, United States	1236/1162	Range 20–44	Self-reported	PE in any pregnancy (10.4)	0.81 (0.61, 1.1)	Age and site (matched), race, parity, age at first birth, body mass index, and menopausal status
				HIP in any pregnancy (13.8)	0.94 (0.73, 1.2)	
Innes and Byers, 2004, United States	2404/9638	Range 22–55 Mean 37.6	Birth records	P in first pregnancy (4.1)	0.86 (0.67, 1.12)	County and date of delivery (matched), age, and age at first birth
Terry et al, 2007, United States	1303/1374	Range 20–98	Self-reported	PE/HIP in any pregnancy (13.6)	0.71 (0.55, 0.93)	Age, age at first birth, body mass index, parity, smoking status, menopausal status, age at menarche, lactation, family history of breast cancer, ethnicity, and education

Abbreviations: CI = confidence interval; HIP = hypertension in pregnancy; HR = hazard ratio; HT = hypertension; ICD = International Classification of Diseases; NR = not reported; OR = odds ratio; P = preeclampsia; PE = preeclampsia/eclampsia; Q1 = lowest quartile; Q4 = highest quartile; RR = relative risk. [a]Only studies referred to in the discussion are included. [b]Among all participants in cohort studies and among controls only in case–control studies. [c]Only incidence rates reported.

closely associated with placental dysfunction than preeclampsia detected at term, and that term preeclampsia may be more strongly related to maternal metabolic factors (Huppertz, 2008; Valensise et al, 2008), such as overweight and obesity (Sohlberg et al, 2012). Furthermore, risk factors for preeclampsia are associated with patterns of blood pressure change in normotensive pregnancies similar to those seen in preeclampsia (Macdonald-Wallis et al, 2011), and gestational hypertension and preeclampsia may be closely related conditions (Villar et al, 2006). The lower breast cancer risk observed for women who experienced hypertension or preeclampsia in their first pregnancy and had a term or post-term birth may indicate that maternal metabolic factors may have an important role.

In conclusion, women who experience hypertensive diseases in pregnancy are at reduced risk of breast cancer. Further research is needed to clarify whether this association can be attributed to pregnancy-specific events or to underlying biological traits. A better understanding of how hypertensive diseases in pregnancy influence breast cancer risk may be useful for our understanding of breast cancer development.

ACKNOWLEDGEMENTS

Epidemiology

REFERENCES

Backe B (1992) Norwegian experiences. Competence of the providers and compliance to the treatment program for antenatal care in Norway. *Int J Technol Assess Health Care* **8**(Suppl 1): 13–19

Baer HJ, Tworoger SS, Hankinson SE, Willett WC (2010) Body fatness at young ages and risk of breast cancer throughout life. *Am J Epidemiol* **171**(11): 1183–1194

Bjorge T, Lukanova A, Jonsson H, Tretli S, Ulmer H, Manjer J, Stocks T, Selmer R, Nagel G, Almquist M, Concin H, Hallmans G, Haggstrom C, Stattin P, Engeland A (2010) Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. *Cancer Epidemiol Biomarkers Prev* **19**(7): 1737–1745

Britt K, Ashworth A, Smalley M (2007) Pregnancy and the risk of breast cancer. *Endocr Relat Cancer* **14**(4): 907–933

Calderon-Margalit R, Friedlander Y, Yanetz R, Deutsch L, Perrin MC, Kleinhaus K, Tiram E, Harlap S, Paltiel O (2009) Preeclampsia and subsequent risk of cancer: update from the Jerusalem Perinatal Study. *Am J Obstet Gynecol* **200**(1): 63. e1–63. e5

Cnattingius S, Torrang A, Ekbom A, Granath F, Petersson G, Lambe M (2005) Pregnancy characteristics and maternal risk of breast cancer. *JAMA* **294**(19): 2474–2480

Cohn BA, Cirillo PM, Christianson RE, van den Berg BJ, Siiteri PK (2001) Placental characteristics and reduced risk of maternal breast cancer. *J Natl Cancer Inst* **93**(15): 1133–1140

Cole SR, Hernan MA (2002) Fallibility in estimating direct effects. *Int J Epidemiol* **31**(1): 163–165

Friedenreich CM (2001) Review of anthropometric factors and breast cancer risk. *Eur J Cancer Prev* **10**(1): 15–32

Huppertz B (2008) Placental origins of preeclampsia: challenging the current hypothesis. *Hypertension* **51**(4): 970–975

Innes KE, Byers TE (1999) Preeclampsia and breast cancer risk. *Epidemiology* **10**(6): 722–732

Innes KE, Byers TE (2004) First pregnancy characteristics and subsequent breast cancer risk among young women. *Int J Cancer* **112**(2): 306–311

Kelsey JL, Gammon MD, John EM (1993) Reproductive factors and breast cancer. *Epidemiol Rev* **15**(1): 36–47

Larsen IK, Småstuen M, Parkin DM, Bray F (2007) Data Quality at the Cancer Registry of Norway. *Cancer in Norway 2006 – Cancer Incidence, Mortality, Survival and Prevalence in Norway*. Cancer Registry of Norway: Oslo

Ma H, Henderson KD, Sullivan-Halley J, Duan L, Marshall SF, Ursin G, Horn-Ross PL, Largent J, Deapen DM, Lacey Jr. JV, Bernstein L (2010) Pregnancy-related factors and the risk of breast carcinoma *in situ* and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. *Breast Cancer Res* **12**(3): R35

Macdonald-Wallis C, Tilling K, Fraser A, Nelson SM, Lawlor DA (2011) Established preeclampsia risk factors are related to patterns of blood pressure change in normal term pregnancy: findings from the Avon Longitudinal Study of Parents and Children. *J Hypertens* **29**(9): 1703–1711

Mogren I, Stenlund H, Hogberg U (2001) Long-term impact of reproductive factors on the risk of cervical, endometrial, ovarian and breast cancer. *Acta Oncol* **40**(7): 849–854

Nechuta S, Paneth N, Velie EM (2010) Pregnancy characteristics and maternal breast cancer risk: a review of the epidemiologic literature. *Cancer Causes Control* **21**(7): 967–989

NIPH (2009) Medisinsk fødselsregisters variabeldefinisjon (in Norwegian). Norwegian Institute of Public Health website. Oslo. Accessed 27 March 2012. Available from http://www.fhi.no/dokumenter/ 8f2fb56c54.pdfhttp://www.fhi.no/dokumenter/46087a62ea.pdf

Polednak AP, Janerich DT (1983) Characteristics of first pregnancy in relation to early breast cancer. A case-control study. *J Reprod Med* **28**(5): 314–318

Sohlberg S, Stephansson O, Cnattingius S, Wikstrom AK (2012) Maternal body mass index, height, and risks of preeclampsia. *Am J Hypertens* **25**(1): 120–125

Talamini R, Franceschi S, Favero A, Negri E, Parazzini F, La Vecchia C (1997) Selected medical conditions and risk of breast cancer. *Br J Cancer* **75**(11): 1699–1703

Tamimi R, Lagiou P, Vatten LJ, Mucci L, Trichopoulos D, Hellerstein S, Ekbom A, Adami HO, Hsieh CC (2003) Pregnancy hormones, pre-eclampsia, and implications for breast cancer risk in the offspring. *Cancer Epidemiol Biomarkers Prev* **12**(7): 647–650

Terry MB, Perrin M, Salafia CM, Zhang FF, Neugut AI, Teitelbaum SL, Britton J, Gammon MD (2007) Preeclampsia, pregnancy-related hypertension, and breast cancer risk. *Am J Epidemiol* **165**(9): 1007–1014

Thompson WD, Jacobson HI, Negrini B, Janerich DT (1989) Hypertension, pregnancy, and risk of breast cancer. *J Natl Cancer Inst* **81**(20): 1571–1574

Trogstad L, Magnus P, Stoltenberg C (2011) Pre-eclampsia: Risk factors and causal models. *Best Pract Res Clin Obstet Gynaecol* **25**(3): 329–342

Troisi R, Innes KE, Roberts JM, Hoover RN (2007) Preeclampsia and maternal breast cancer risk by offspring gender: do elevated androgen concentrations play a role? *Br J Cancer* **97**(5): 688–690

Troisi R, Weiss HA, Hoover RN, Potischman N, Swanson CA, Brogan DR, Coates RJ, Gammon MD, Malone KE, Daling JR, Brinton LA (1998) Pregnancy characteristics and maternal risk of breast cancer. *Epidemiology* **9**(6): 641–647

Valensise H, Vasapollo B, Gagliardi G, Novelli GP (2008) Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. *Hypertension* **52**(5): 873–880

Vatten LJ, Forman MR, Nilsen TI, Barrett JC, Romundstad PR (2007) The negative association between pre-eclampsia and breast cancer risk may depend on the offspring's gender. *Br J Cancer* **96**(9): 1436–1438

Vatten LJ, Romundstad PR, Trichopoulos D, Skjaerven R (2002a) Pre-eclampsia in pregnancy and subsequent risk for breast cancer. *Br J Cancer* **87**(9): 971–973

Vatten LJ, Romundstad PR, Trichopoulos D, Skjaerven R (2002b) Pregnancy related protection against breast cancer depends on length of gestation. *Br J Cancer* **87**(3): 289–290

Vatten LJ, Skjaerven R (2004) Offspring sex and pregnancy outcome by length of gestation. *Early Hum Dev* **76**(1): 47–54

Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba'aqeel H, Farnot U, Bergsjo P, Bakketeig L, Lumbiganon P, Campodonico L, Al-Mazrou Y, Lindheimer M, Kramer M (2006) Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? *Am J Obstet Gynecol* **194**(4): 921–931

Epidemiology